Curi Bio Analysis
What is Curi Bio?
Curi Bio develops human-relevant platforms using human iPSC-derived tissues to create structurally mature and predictive 3D models of cardiac, skeletal muscle, and disease states. The company's biosystems enable clinically relevant functional analyses such as contractility and calcium signaling. AI/ML-enabled analytics platforms process data to assess drug safety, efficacy, and potency. Services include compound screening, assay development, and discovery support for preclinical drug development.
Location
Seattle, United States
Employees
11-50
Founded
2015
Funding Status
Series A
Product Features & Capabilities
- Mantarray™ 3D tissue contractility analysis
- Mantarray Mini Plates for fewer cells, more data
- Nautilai™ voltage and calcium imaging
- Stingray™ tissue maturation
- NanoSurface™ plates for structural maturation
- Pulse™ high-throughput video contractility software
- Celo.Cardiomyocytes and skeletal muscle myoblasts
- Curi Engine™ services for compound profiling, assay development, and discovery
Use Cases
Screen compounds for cardiac toxicity using 3D engineered heart tissues; Test drug efficacy on Duchenne muscular dystrophy disease models; Evaluate muscle contractility in 2D and 3D skeletal muscle models; Perform high-throughput screening of drug candidates with Pulse™ software; Develop new assays using Curi Engine™ services; Assess calcium signaling in cardiac cells with Nautilai™; Validate drug potency in mature 3D muscle tissues
Other Considerations
Recognized as a 2024 Deloitte Technology Fast 500 winner; Named a 2021 Fast Company World Changing Ideas Award finalist; Selected as a 2021 AI & Data category finalist in Fast Company's World Changing Ideas Awards; Wins 2020 Xconomy Big Idea of the Year Award; Wins 2020 Tibbetts Award; Finalist for 2021 Edison Award
See something that needs updating? Suggest edits to this profile.